Quarter
Charts

BIOVENTUS INC.

BVS

CIK 0001665988 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$158M
↑+2.8% +$4Mvs FY2024 (Q4)
Operating Income
$19M
Net Income
$14M
Gross Profit
$109M
↑+6.0% +$6Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
49/100
  • Profitability
    34ROIC 11.7% (10% = solid, 20%+ = moat)
  • Liquidity
    60Current Ratio 1.70 (above 1.5 = solid)
  • Leverage
    24D/E 1.52 (under 0.5 = conservative)
  • Efficiency
    47Asset Turnover 0.80x (1.0+ = capital-efficient)
  • Growth
    26Revenue YoY +2.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 12.3% · trend +14.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project BVS's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$18.00
Total enterprise IV
$1.24B
Diluted shares
0.07B
Terminal PV
$899M (72% of total)
Year-5 FCF
$106M
YearProjected FCFDiscounted PV
+1$78M$71M
+2$84M$70M
+3$91M$68M
+4$98M$67M
+5$106M$66M
Terminal$1.45B$899M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$3M
investment in PP&E
Stock-based comp (TTM)
$13M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$684M
everything owned
Total liabilities
$455M
everything owed
Stockholders' equity
$184M
shareholder claim
Net debt
$228M
LT debt minus cash

Recent performance · 26 quarters

Revenue↑+2.8% +$4M
$158M
Net Income
$15M
Free Cash Flow↑+99.4% +$19M
$37M
Operating Margin
12.3%

Drill down

BVS Sankey

See BIOVENTUS INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

BVS Charts

26 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

BVS Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics